Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2020 Elsevier Inc. All rights reserved. Islet transplantation has been funded in the UK by the National Health Service since 2008. Pancreata are optimally procured by the National Organ Retrieval Service and shared equitably between islet and solid organ recipients. Islets are isolated at three central clean room facilities and transported to one of the seven geographically distributed multidisciplinary assessment, transplant, and follow-up centers. Recipients with life-threatening hypoglycemia despite optimized conventional therapy receive up to two sequential islet transplants with the goal of preventing further severe hypoglycemia and attaining optimal overall glycemic control. Over the first 10 years of the program, 243 islet transplants have been performed in 144 recipients. The majority of these (85%) have been islet transplants alone. Non-inferiority of transported versus locally isolated islets has been confirmed with 88% graft function at 1 year associated with median severe hypoglycemia rate of zero and HbA1c 6.8%. This has provided a sustainable platform for ongoing service provision and further innovation.

Original publication

DOI

10.1016/B978-0-12-814833-4.00049-6

Type

Chapter

Book title

Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas: Volume 1

Publication Date

01/01/2019

Pages

613 - 623